stockrowAbsci Corporation
ABSIAbsci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024.
- Revenue
- −46.4%
- EPS
- +12.5%
- Free cash flow
- −71.7%
- Total debt
- −93.0%
Quarter to June 2026, against a year earlier
Follow ABSI
Alert me
Absci Corporation (ABSI) Return on invested capital
Absci Corporation's return on invested capital over the twelve months to 30 June 2026 was −174.7%, down 11.4 percentage points from fiscal 2025 (−163.4%). Over the past ten years it has ranged from −168.0% (fiscal 2020) to −42.8% (fiscal 2021); the current reading is higher than 29% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −163.4% | (39.07) |
| FY2024 | −124.3% | (21.52) |
| FY2023 | −102.8% | (40.22) |
| FY2022 | −62.6% | (19.73) |
| FY2021 | −42.8% | 125.18 |
| FY2020 | −168.0% | (6.01) |
| FY2019 | −162.0% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVAX Novavax, Inc. compare | 0.00% |
| GENB Generate Biomedicines, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −2.26% |
| AGIO Agios Pharmaceuticals, Inc. compare | −75.0% |
| MAZE Maze Therapeutics, Inc. compare | −112.4% |
| ABSI Absci Corporation | −174.7% |
| KLRA Kailera Therapeutics, Inc. compare | −182.9% |
| STOK Stoke Therapeutics, Inc. compare | −482.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)